Literature DB >> 911604

Factors influencing plasma phenobarbitone levels in epileptic patients.

M J Eadie, C M Lander, W D Hooper, J H Tyrer.   

Abstract

1 Various statistical techniques were used to study the effects of age, sex and concurrent therapy with other anticonvulsants on the relation between plasma phenobarbitone levels and doses of (i) phenobarbtione, (ii) methylphenobarbitone or (iii) primidone, in epileptic patients. 2 Methylphenobarbitone and primidone are converted to phenobarbitone in the body. The mean doses of phenobarbitone, methylphenobarbitone and primidone which produced the same plasma phenobarbitone level (15 microgram/ml) were, respectively, 1.75,2.75 and 7.75 mg kg-1 day-1. 3 For both phenobarbitone and methylphenobarbitone dose requirement to achieve a given plasma phenobarbitone level fell progressively with age. Sex influenced the relation between plasma phenobarbitone level and phenobarbitone or methylphenobarbitone dose. Interactions were detected between primidone and both phenytoin and carbamazepine. 4 In individual patients, within the limits of dosage studied, the relation between plasma phenobarbitone level and drug dose was not rectilinear if phenobarbitone itself was taken, but was rectilinear if methylphenobarbitone was taken.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 911604      PMCID: PMC1429157          DOI: 10.1111/j.1365-2125.1977.tb00783.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  13 in total

1.  Interaction of phenytoin and primidone.

Authors:  E H Reynolds; G Fenton; P Fenwick; A L Johnson; M Laundy
Journal:  Br Med J       Date:  1975-06-14

2.  Simultaneous assay of methylphenobarbitone and phenobarbitone using gas-liquid chromatography with on-column butylation.

Authors:  W D Hooper; D K Dubetz; M J Eadie; J H Tyrer
Journal:  J Chromatogr       Date:  1975-07-02

3.  N-methylated derivatives of barbituric acid, hydantoin and oxazolidinedione used in the treatment of epilepsy.

Authors:  T C BUTLER; W J WADDELL
Journal:  Neurology       Date:  1958-04       Impact factor: 9.910

4.  Drug estimation in the treatment of epilepsy.

Authors:  A Richens
Journal:  Proc R Soc Med       Date:  1974-12

5.  Chronic and severe phenobarbital intoxication in a child treated with primidone and diphenylhydantoin.

Authors:  J T Wilson; G R Wilkinson
Journal:  J Pediatr       Date:  1973-09       Impact factor: 4.406

6.  Diphenylhydantoin dosage.

Authors:  M J Eadie; J H Tyrer; W D Hooper
Journal:  Proc Aust Assoc Neurol       Date:  1973

7.  The relationship of the anticonvulsant properties of primidone to phenobarbital.

Authors:  B B Gallagher; D B Smith; R H Mattson
Journal:  Epilepsia       Date:  1970-09       Impact factor: 5.864

8.  A clinical study of serum primidone levels.

Authors:  H E Booker; K Hosokowa; R D Burdette; B Darcey
Journal:  Epilepsia       Date:  1970-12       Impact factor: 5.864

9.  Variation in response to anticonvulsants in a group of epileptic patients.

Authors:  R D Travers; E H Reynolds; B B Gallagher
Journal:  Arch Neurol       Date:  1972-07

10.  Preliminary observations on the clinical pharmacology of carbamazepine ('Tegretol').

Authors:  W D Hooper; D K Dubetz; M J Eadie; J H Tyrer
Journal:  Proc Aust Assoc Neurol       Date:  1974
View more
  14 in total

Review 1.  Therapeutic drug monitoring--antiepileptic drugs.

Authors:  M J Eadie
Journal:  Br J Clin Pharmacol       Date:  1998-09       Impact factor: 4.335

Review 2.  Anticonvulsant therapy in aged patients. Clinical pharmacokinetic considerations.

Authors:  I Bernus; R G Dickinson; W D Hooper; M J Eadie
Journal:  Drugs Aging       Date:  1997-04       Impact factor: 3.923

Review 3.  Clinically significant pharmacokinetic drug interactions with carbamazepine. An update.

Authors:  E Spina; F Pisani; E Perucca
Journal:  Clin Pharmacokinet       Date:  1996-09       Impact factor: 6.447

4.  The practical use of anticonvulsants in pediatric practice.

Authors:  N Buchanan
Journal:  Indian J Pediatr       Date:  1986 Jan-Feb       Impact factor: 1.967

Review 5.  Pharmacokinetic variability of phenobarbital: a systematic review of population pharmacokinetic analysis.

Authors:  Janthima Methaneethorn; Nattawut Leelakanok
Journal:  Eur J Clin Pharmacol       Date:  2020-10-19       Impact factor: 2.953

Review 6.  Pharmacokinetic interactions between antiepileptic drugs. Clinical considerations.

Authors:  R Riva; F Albani; M Contin; A Baruzzi
Journal:  Clin Pharmacokinet       Date:  1996-12       Impact factor: 6.447

7.  Factors influencing plasma concentrations of ethosuximide.

Authors:  G A Smith; L McKauge; D Dubetz; J H Tyrer; M J Eadie
Journal:  Clin Pharmacokinet       Date:  1979 Jan-Feb       Impact factor: 6.447

8.  Low-dose phenobarbitone as an indicator of compliance with drug therapy.

Authors:  M Feely; J Cooke; D Price; S Singleton; A Mehta; L Bradford; R Calvert
Journal:  Br J Clin Pharmacol       Date:  1987-07       Impact factor: 4.335

Review 9.  Anticonvulsant drugs. An update.

Authors:  M J Eadie
Journal:  Drugs       Date:  1984-04       Impact factor: 9.546

Review 10.  Clinical pharmacokinetics of antiepileptic drugs in paediatric patients. Part I: Phenobarbital, primidone, valproic acid, ethosuximide and mesuximide.

Authors:  D Battino; M Estienne; G Avanzini
Journal:  Clin Pharmacokinet       Date:  1995-10       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.